TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3

• Main Authors: Shihai Liu, Jing Qiu, Guifang He, Weitai He, Changchang Liu, Duo Cai, Huazheng Pan
• Format: Article
• Language: English
• Published: BMC 2021-01-01
• Series: Cancer Cell International
• Subjects: Tumor necrosis factor-related apoptosis-inducing ligand; Wnt pathway; Hepatocellular carcinoma
• Online Access: https://doi.org/10.1186/s12935-020-01724-8

Abstract Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce substantial cytotoxicity in tumor cells but rarely exert cytotoxic activity on non-transformed cells. In the present study, we therefore evaluated interactions between TRAIL and IER3 via co-immunoprecipitation and immunofluorescence analyses, leading us to determine that these two proteins were able to drive the apoptotic death of hepatocellular carcinoma (HCC) cells and to disrupt their proliferative and migratory abilities both in vitro and in vivo. From a mechanistic perspective, we determined that TRAIL and IER3 were capable of inhibiting Wnt/β-catenin signaling. Together, these results indicate that TRAIL can control the pathogenesis of HCC at least in part via interacting with IER3 to inhibit Wnt/β-catenin signaling, thus indicating that this TRAIL/IER3/β-catenin axis may be a viable therapeutic target in HCC patients.